The article reports that rapid adoption of Food & Drug Administration (FDA)-approved biosimilars is feasible, measurable, and scalable and pharmacists should lead the charge. Topics include results of a pharmacy-driven intervention showed a statistically significant increase in biosimilar adoption; and pharmacy-based substitution approach allows providers to focus on front-end patient care instead of the back-end medication substitution process.